Dissemin is shutting down on January 1st, 2025

Published in

American Association for the Advancement of Science, Science, 6424(363), 2019

DOI: 10.1126/science.aau0629

Yearbook of Paediatric Endocrinology, 2019

DOI: 10.1530/ey.16.1.5

Links

Tools

Export citation

Search in Google Scholar

CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

CRISPRa corrects haploinsufficient obesity Loss-of-function mutation in one gene copy, termed haploinsufficiency, can lead to insufficient protein levels and result in human disease. Matharu et al. tested whether a CRISPR-based activation system (CRISPRa) could rescue a haploinsufficient phenotype by increasing the gene expression levels of the existing normal copy (see the Perspective by Montefiori and Nobrega). By delivering this system into the mouse hypothalamus using adeno-associated virus, they rescued the obesity phenotype caused by haploinsufficiency of either of two genes known to promote obesity when mutated in mice and humans. These results highlight the translational potential of the CRISPR activation system to treat haploinsufficient disease. Science , this issue p. eaau0629 ; see also p. 231